EPHA3 and neoplasm: The reduction in receptor activity conferred by the point mutations of EPHA3 found in cancers, and ligand- and EPHA3-dependent apoptosis of tumor and stroma cells upon receptor agonist treatment suggested that wild-type EPHA3 has anti-tumorigenic properties in NSCLC [19, 43–46].